Prolactinomas Resistant to Standard Doses of Cabergoline : A multicenter study of 92 patients

in European Journal of Endocrinology (2012), 167

Clinical characterization of cabergoline resistant prolactinomas : a multicenter experience on 92 patients

in ENEA Munich - abstract book (2011, December)

Faut-il rechercher des anomalies génétiques constitutionnelles des gènes AIP et MEN1 chez un sujet jeune atteint d'adénome hypophysaire isolé sporadique ?

in Annales d'Endocrinologie - 28ème congrès de la société Française d'Endocrinologie (2011)

Caractéristiques des prolactinomes résistants aux agonistes dopaminergiques

in Annales d'Endocrinologie (2010, September), 71(5), 347

Cyclin dependent kinase inhibitor 1B (CDKN1B) gene mutations in FIPA

in European Neuroendocrine Association - Liège, 22-25 septembre 2010 (2010, September)

Comprehensive study about the characteristics of 80 dopaminergic agonist resistants prolactinomas

in European Neuroendocrine Association - Liège, 22-25 septembre 2010 (2010, September)

Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study.

in Journal of Clinical Endocrinology and Metabolism (2005), 90(2), 841-848

There are few effective, safe modalities for the management of Graves' ophthalmopathy (GO), a cell-mediated immune comorbidity of thyroid disease. Somatostatin analogs inhibit lymphocyte proliferation and ... [more ▼]

There are few effective, safe modalities for the management of Graves' ophthalmopathy (GO), a cell-mediated immune comorbidity of thyroid disease. Somatostatin analogs inhibit lymphocyte proliferation and activation, and accumulate in the orbital tissue of patients with GO. A double-blind, placebo-controlled study of a long-acting somatostatin analog [16 wk of long-acting release formulation of octreotide (octreotide-LAR)] was conducted in 51 patients with mild active GO with the aim of preventing deterioration and precluding the need for more aggressive therapeutic modalities, such as glucocorticoids or radiotherapy. No treatment effect was observed for the primary end point (a composite parameter defining the outcome as either success or failure on the basis of changes in class/grade of the severity index and Clinical Activity Scale of GO). The Clinical Activity Scale score was reduced for patients treated with octreotide-LAR, but without any significant difference with respect to patients receiving placebo. However, octreotide-LAR significantly reduced proptosis (as measured by exophthalmometry). This was associated with nonsignificant differences in favor of octreotide-LAR in a series of proptosis-related parameters: class III grade, opening of the upper eyelid, the difference in ocular pressure between primary position and upgaze, and extraocular muscle involvement. By magnetic resonance imaging evaluation the extraocular muscle volumes appeared reduced, but nonsignificantly. No significant correlation between the initial uptake of the somatostatin analog indium-labeled and the response to treatment was observed. One patient in the octreotide-LAR group developed gallstones. In this study, octreotide-LAR did not seem suitable to mitigate activity in mild GO. Surprisingly, it significantly reduced proptosis, one of the most debilitating symptoms of GO. Additional studies are warranted to define the benefit to risk ratio of the somatostatin analogs in this indication. [less ▲]

L'octréotide LP dans le traitement des ophtalmopathies basedowiennes incipiens : Evaluation prospective VS placebo

in XXIème Congrès de la Société Française d'Endocrinologie - Abstract book (2004)

Absence d'effet de l'octréotide sur les concentrations plasmatiques de l'hormone de croissance placentaire

in Annales d'Endocrinologie (1996), 57(4), 335